Sarepta Therapeutics shares are trading lower after the company reported worse-than-expected Q2 sales results and issued FY25 net product revenue guidance below estimates. Also, Piper Sandler maintained an Overweight rating on the stock and lowered its price target from $205 to $200.
Portfolio Pulse from Benzinga Newsdesk
Sarepta Therapeutics shares are trading lower after reporting worse-than-expected Q2 sales results and issuing FY25 net product revenue guidance below estimates. Piper Sandler maintained an Overweight rating but lowered its price target from $205 to $200.
August 08, 2024 | 12:20 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sarepta Therapeutics shares are trading lower due to worse-than-expected Q2 sales results and lower FY25 net product revenue guidance. Piper Sandler maintained an Overweight rating but reduced the price target from $205 to $200.
The disappointing Q2 sales results and lower FY25 revenue guidance are likely to negatively impact investor sentiment and the stock price in the short term. Although Piper Sandler maintained an Overweight rating, the reduction in the price target indicates a less optimistic outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100